IMM20184, IMM20190, and IMM20253 drug combination

three neutralizing antibodies directed at different areas of SARS-CoV-2 spike protein

Also Known As:

IMM-BCP-01; IMM20184, IMM20190, IMM20253; IMM20184, IMM20190, IMM20253 drug combination; IMM20184-IMM20190-IMM20253; IMMBCP-01; IMMBCP01

Networked: 1 relevant articles (0 outcomes, 0 trials/studies)

1.	Bingaman-Steele, Jamie L: 1 article (01/2022)
2.	DiMuzio, Jillian M: 1 article (01/2022)
3.	Diamond, Michael S: 1 article (01/2022)
4.	Dowling, John P: 1 article (01/2022)
5.	Finn, James P: 1 article (01/2022)
6.	Geising, Dennis H: 1 article (01/2022)
7.	Griffiths, Anthony: 1 article (01/2022)
8.	Heimbach, Baron C: 1 article (01/2022)
9.	Henriquez, Noeleya: 1 article (01/2022)
10.	Honko, Anna N: 1 article (01/2022)

1.	Infections 01/01/2022 - "Our preclinical data demonstrated that the three-antibody cocktail IMM-BCP-01 could be a promising means for preventing or treating infection of SARS-CoV-2 variants of concern, including Omicron BA.1 and BA.2, in susceptible individuals."
2.	COVID-19 01/01/2022 - "Using an unbiased interrogation of the memory B cell repertoire of patients with convalescent COVID-19, we identified human antibodies with broad antiviral activity in vitro and efficacy in vivo against all tested SARS-CoV-2 variants of concern, including Delta and Omicron BA.1 and BA.2. Here, we describe an antibody cocktail, IMM-BCP-01, that consists of three patient-derived broadly neutralizing antibodies directed at nonoverlapping surfaces on the SARS-CoV-2 Spike protein. "

1.	Antiviral Agents (Antivirals)
2.	Antibodies
3.	Combined Antibody Therapeutics
4.	Broadly Neutralizing Antibodies
5.	N-methyl-valyl-amiclenomycin (BA 2)
6.	N-(2-cyanoethylene)urea (BA 1)
7.	SARS-CoV-2 spike protein